Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
$125.00 Tirzepatide is a novel dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), developed by Eli Lilly and commercialised as Mounjaro (type 2 diabetes) and Zepbound (obesity)
Biological Activities of GLP-1
Those experiencing persistent nausea or food aversions, common side effects of these medicines, may further restrict their dietary variety, potentially compromising micronutrient intake including B12
Make gradual changes: Losing weight too fast can cause rapid hormone shifts that can result in the loss of hair and skin issues
A patient cohort study from the Cleveland Clinic tracked 156 patients who stopped tirzepatide after 48+ weeks
